The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...
NeuroInvestment today announced the release ofits July/August issue, which overviews the CNS sector at midyear, andpreviews the second half of 2008. The major news at midyear was theAlzheimer's data which came from high-profile programs at Elan/Wyeth and atMyriad Genetics. The issue takes a hard look at those results,...
Myriad Genetics Inc.'s stock price rebounded Tuesday, rising nearly 13 percent after losing more than 5 percent Monday when it announced it would discontinue development of an Alzheimer's disease drug. Myriad stock closed at $51.39 on Tuesday, up $5.87. During the past year,...
A drug under development by Salt Lake-based Myriad Genetics to treat Alzheimer's disease failed in a closely watched late-stage clinical trial, dealing another blow to efforts to combat the illness. Myriad said the drug, called Flurizan, did not improve thinking ability by a...
Myriad Genetics, Inc. (NASDAQ: MYGN)today announced results of the Act-Earli-AD trial, an 18-month Phase 3study of Flurizan tarenflurbil in patients with mild Alzheimer's disease.The study did not achieve statistical significance on either of its primaryendpoints -- cognition and activities of daily living. "We are disappointed that Flurizan failed...
Physician Education Will be a Critical Step in the Adoption of Emerging Alzheimer's Disease Therapies, According to a New Report from Decision Resources WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare...
A class of drugs called gamma-secretase modulators shows potential for treating Alzheimer's disease, a new study suggests. A hallmark of Alzheimer's is so-called amyloid plaque, which develops tangles in the brain. The gamma-secretase modulators reduce the production of long pieces of amyloid beta protein that stick together and form...
PARIS AFP — Scientists on Wednesday said they had developed an experimental drug to combat Alzheimer's that employs a double-pronged attack against a rogue protein fingered for causing the disease. The drug -- still in clinical trials -- is part of a class called gamma-secretase modulators...
Myriad Genetics, Inc. (NASDAQ: MYGN)announced today that the mechanism of action of Flurizan® tarenflurbil-- its drug candidate for the treatment of Alzheimer's disease, iselucidated in the scientific journal Nature. The article,"Substrate-targeting Gamma-secretase Modulators," will be published in theJune 12, 2008 issue of Nature. Previous studies, in vitro, in...
Sales of Currently Dominant Acetylcholinesterase Inhibitors Will Decrease by Nearly Half Over the Next Decade, According to a New Report from Decision Resources WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare...
Myriad Genetics, Inc. (NASDAQ: MYGN)( www.myriad.com ) today announced the selection of H. Lundbeck A/S forEuropean commercialization of Flurizan®, Myriad's lead therapeuticcandidate for the treatment of Alzheimer's disease. Myriad and Lundbeck have entered into a European commercializationagreement under which Lundbeck will have rights to market and sell Flurizanin the European...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c77639) has announced the addition of Decision Resources new report: Emerging Drug Targets in Alzheimer's Disease to their offering. Introduction The lack of effective treatments for Alzheimer's disease AD and an aging population create an enormous opportunity...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c68786) has announced the addition of "Stakeholder Insight: Alzheimers Disease -- Prescribing Trends Indicate That Neurologists Are Not Adhering to Guidelines" to their offering. A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a...
Myriad Genetics, Inc. (NASDAQ: MYGN)( www.myriad.com ) announced today that it has completed enrollment ofpatients in its global Phase 3 clinical trial of FlurizanTMtarenflurbil in Alzheimer's disease. The global Phase 3 clinical trial, ActEarliAD, is a multinational,randomized, double-blind, placebo-controlled study of Flurizan in over 800patients with mild Alzheimer's disease, who...
Myriad Genetics Inc. shares climbed the most in two months after the company said its experimental drug was able to halt symptoms of mild Alzheimer's disease significantly better than a placebo. The shares rose $1.40, or 4.5 percent, to close at $32.63 Monday on the Nasdaq Stock...
M2 PRESSWIRE-5 March 2007-Biotech News: Morning Alert for Myriad Genetics IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:05032007 Morning Alert for Myriad Genetics Inc (NASDAQ:MYGN) There are a myriad of diseases out there, and Myriad Genetics is working on figuring out which...
Myriad Genetics, Inc. (NASDAQ: MYGN)( www.myriad.com ) announced today that it presented additional results ofits completed Phase 2 follow-on study of FlurizanTM in patients withmild Alzheimer's disease atthe annual meeting of the American Association for Geriatric PsychiatryAAGP, held March 1-4, 2007 in New Orleans. The data...
M2 PRESSWIRE-6 February 2007-Biotech News: Shareholders alert for Myriad Genetics IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:06022007 Shareholders alert for Myriad Genetics Inc (NASDAQ:MYGN) There are a myriad of diseases out there, and Myriad Genetics is working on figuring out which...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47291) has announced the addition of Espicom Business Intelligence's CNS Drug Discoveries: Neurodegenerative Disorders Chapter to their offering. This chapter of CNS Drug Discoveries focuses on the Alzheimer's disease and Parkinson's disease sectors of the market for neurodegenerative drugs....
CINCINNATI -- Among the stocks featured in the August 22 edition of Schaeffer's Market Blog are Toll Brothers (NYSE:TOL), Advanced Micro Devices (NYSE:AMD), Myriad Genetics (NASDAQ:MYGN), Salesforce.com (NYSE:CRM), and Intuit (NASDAQ:INTU). Schaeffer's Market Blog is just one of the many free market commentaries written every day at...
Articles 2006-08-22
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Enjoy season-long live scoring and stats in CBSSports.com Free Fantasy Football
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
